Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making-Reference-Cited by-同舟云学术

Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making

Published:2016-10-19 Issue:6 Volume:100 Page:633-646
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Schneeweiss S¹,Eichler H-G²,Garcia-Altes A³,Chinn C⁴,Eggimann A-V⁵,Garner S⁶,Goettsch W⁷,Lim R⁸,Löbker W⁹,Martin D¹⁰,Müller T⁹,Park BJ¹¹,Platt R¹²,Priddy S¹³,Ruhl M¹⁴,Spooner A¹⁵,Vannieuwenhuyse B¹⁶,Willke RJ¹⁷

Affiliation:

1. Division of Pharmacoepidemiology (DoPE), Department of Medicine; Brigham & Women's Hospital; Boston Massachusetts USA

2. European Medicines Agency (EMA); London United Kingdom

3. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS); Barcelona Spain

4. Sanofi; Paris France

5. Bluebird Bio, Inc.; Cambridge Massachusetts USA

6. National Institute for Health and Care Excellence (NICE); London United Kingdom

7. National Health Care Institute, Diemen and Division of Pharmacoepidemiology and Clinical Pharmacology; Utrecht Institute for Pharmaceutical Sciences; Utrecht The Netherlands

8. Health Products and Food Branch; Health Canada; Ottawa Ontario Canada

9. Gemeinsamer Bundesausschuss (GBA); Abteilung Arzneimittel; Berlin Germany

10. Center for Drug Evaluation and Research; U.S. Food and Drug Administration; Silver Spring Maryland USA

11. Seoul National University, College of Medicine, Department of Preventive Medicine; Seoul South Korea

12. Department of Population Medicine; Harvard Medical School and Harvard Pilgrim Healthcare Institute; Boston Massachusetts USA

13. Comprehensive Health Insights (CHI), Humana; Louisville Kentucky USA

14. Aetion Inc.; New York NY USA

15. Health Products Regulatory Authority (HPRA); Dublin Ireland

16. Innovative Medicine Initiative - European Medical Information Framework, Janssen Pharmaceutica Research and Development; Beerse Belgium

17. International Society for Pharmacoeconomics and Outcomes Research; Lawrenceville New Jersey USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference70 articles.

1. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes;Kesselheim;Clin. Pharmacol. Ther.,2015

2. Adaptive licensing: taking the next step in the evolution of drug approval;Eichler;Clin. Pharmacol. Ther.,2012

3. A review of uses of health care utilization databases for epidemiologic research on therapeutics;Schneeweiss;J. Clin. Epidemiol.,2005

4. Guidelines for good pharmacoepidemiology practices (GPP);The International Society of Pharmacoepidemiology;Pharmacoepidemiol. Drug Saf.,2008

5. Federal Register Guidance for industry and Food and Drug Administration staff on best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data; availability https://www.federalregister.gov/documents/2013/05/14/2013-11361/guidance-for-industry-and-food-and-drug-administration-staff-on-best-practices-for-conducting-and

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to promote patient‐centeredness within the healthcare industry: A grey‐based multicriteria decision making methods;Journal of Evaluation in Clinical Practice;2024-07-05

2. When Will Real-World Data Fulfill Its Promise to Provide Timely Insights in Oncology?;JCO Clinical Cancer Informatics;2024-06

3. Scoping review of the recommendations and guidance for improving the quality of rare disease registries;Orphanet Journal of Rare Diseases;2024-05-06

4. ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): a screening tool to assess the potential for real-world data sources to support creation of credible real-world evidence for regulatory decision-making;Health Services and Outcomes Research Methodology;2023-11-29

5. Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies;Pharmacoepidemiology and Drug Safety;2023-03-29